Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04989543
Other study ID # C1664
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 24, 2020
Est. completion date November 3, 2021

Study information

Verified date April 2021
Source Larena SAS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It aims to determine and compare the degree of vaginal bacterial alpha diversity in the absence (healthy population) or presence of bacterial vaginosis (pathological population).


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date November 3, 2021
Est. primary completion date December 3, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Woman aged between = 18 and = 45 years old, - In good general health (outside the gynaecological sphere), i.e. no chronic pathology and not taking medication at the time of inclusion and/or long-term, - Woman with a healthy or pathological vaginal flora according to Amsel's clinical diagnosis and Nugent's score : Population with bacterial vaginosis (verification of at least the following 3 criteria + Nugent score): - Vaginal pH > 4.5 - greyish, homogenous vaginal secretions adhering to the vaginal wall - characteristic vaginal odour of "rotten fish" after contact of the vaginal discharge with a few drops of 10% potash ("sniff test") - Presence of "Clue Cells" in the microscopic examination of fresh vaginal secretions. Clue cells are cells of the ectocervix lined with gram-negative bacilli. - Nugent Score = 7 Healthy population (Verification of at least 3 following criteria + Nugent score) : - Absence of vaginal pH > 4.5 - No greyish, homogenous vaginal secretions adhering to the vaginal wall - No characteristic vaginal odour of "rotten fish" after contact of the vaginal discharge with a few drops of 10% potash ("sniff test"). - Absence of "Clue Cells" on microscopic examination of fresh vaginal secretions. Clue cells" are cells of the ectocervix lined with gram-negative bacilli. - Nugent Score =3 - Able and willing to participate in the research by complying with the procedures of the protocol, especially regarding vaginal sampling, - Having given its free, informed and written consent. Exclusion Criteria: - Patient during menstruation, - Patient who has had vaginal sex within 48 hours, - Patient with irregular menstrual cycles, - Patient undergoing preventive or curative treatment for vaginal infections, - Patients suffering from other diseases of the vagina (herpes, chlamydia, syphillis), - Patients undergoing antibiotic or antifungal treatments or taken less than 3 months ago, - Patient under probiotic or prebiotic complementation or taken less than a month ago, - Patient with systemic or immunodeficient disease, - Patient with an alcohol consumption of more than 2 glasses per day, - Pregnant or breastfeeding woman, or woman planning to become pregnant within the next 8 weeks, or woman in the post-partum period, - Patient unable to understand information related to the study (mental or linguistic disability), - Patient participating or having participated within the previous 3 months in another clinical trial, or in a period of exclusion from a clinical trial, - Patient not affiliated to a social security scheme.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
vaginal swabs
Nugent score: Vaginal swabbing with the dry swab, make two smears on slides. Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab

Locations

Country Name City State
France Institut FOURNIER Paris

Sponsors (3)

Lead Sponsor Collaborator
Larena SAS CEN Biotech, Luxia Scientific

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other - Identify threshold values of bacterial diversity beyond which a bacterial vaginosis would be established; - Validate these thresholds by comparison with the Nugent score and the Amsel diagnosis. The possible thresholds of bacterial diversity above which bacterial vaginosis is observed will be validated by comparison with the Nugent score made during the screening visit and the Amsel diagnosis. Day 0
Primary Determine and compare the degree of vaginal bacterial alpha diversity in the absence (healthy population) or presence of bacterial vaginosis (pathological population). The degree of vaginal bacterial alpha diversity in healthy and pathological conditions (bacterial vaginosis) will be evaluated by the Shannon index. It will be determined by the identification of the bacterial species (16s RNA analysis) present on a vaginal swab taken during the selection visit. Day 0
Secondary Determine and compare in healthy versus pathological conditions (bacterial vaginosis) : - vaginal specific richness in enterotypes, - The diversity of vaginal bacterial species by other indices, - The overall composition of the vaginal microbiota. Enterotypic richness will be assessed by 16 S analyses on the vaginal swab taken during the selection visit.
The a-diversity will be calculated using other indices.
The overall composition of the vaginal microbiota will be assessed from a taxonomic point of view on the vaginal swab taken during the selection visit by calculating the percentage (relative quantification).
Day 0
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02558179 - Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method N/A
Completed NCT02314429 - Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis Phase 1
Completed NCT02272231 - Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
Completed NCT02139839 - Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 Phase 0
Recruiting NCT01448291 - Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Phase 4
Recruiting NCT03500107 - Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial N/A
Completed NCT00153517 - Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy Phase 2
Completed NCT02641717 - Validity of Patient-Collected Wet Mounts N/A
Terminated NCT03943823 - Postmenopausal Pessary Users: Estrogen Versus Trimosan Phase 4
Completed NCT03134924 - Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention "WASH-2" N/A
Completed NCT01293643 - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Phase 3
Terminated NCT01153958 - Colposeptine for the Treatment of Bacterial Vaginosis Phase 4
Completed NCT00484653 - Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman N/A
Completed NCT05649735 - EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS N/A
Completed NCT02860845 - Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Phase 4
Not yet recruiting NCT00491270 - Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Phase 3
Completed NCT01055106 - Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis Phase 2
Terminated NCT01322971 - Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population N/A
Completed NCT04171947 - Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment N/A
Completed NCT02392026 - Safety and Tolerability of Metronidazole Gel 1.3% Phase 4